Different oral hormone therapy regimens result in large and discordant metabolomic effects that impact the risk for coronary heart disease. 62% of metabolites significantly changed with randomized conjugated equine estrogens (CEE) and 52% with combined CEE and medroxyprogesterone acetate (MPA) treatments.